News

If waste DNA or RNA remains in cells, it can lead to diseases such as Alzheimer’s and autoimmune conditions. Writing in Nucleic Acids Research, scientists led by Oliver Daumke of the Max Delbrück Center describe the role one enzyme plays in removing this waste.

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.

Simon Haas has been awarded the Lisec-Artz Prize, endowed with €10,000, for his single-cell analysis of communication between stem and immune cells in blood cancer. The University of Bonn Foundation established this prize to honor outstanding early-career cancer researchers.

Organoids help researchers understand biological processes in health and in disease. It is, however, difficult to influence the way in which they organize themselves into complex tissues. Now a group led by Nikolaus Rajewsky has found a new way to do so. They report their work in Nature Methods.

Bartter syndrome type 3 is the result of several structural variants in the genome. By using long-read sequencing, Janine Altmüller and her team from the Max Delbrück Center, the BIH and University Hospital Cologne mapped out the rare disease in unprecedented detail. They have now reported their findings in “Genome Medicine.”

Cancer cells are capable of escaping chemotherapy and radiotherapy by activating a signaling pathway that prevents them from dying. Researchers led by Claus Scheidereit at the Max Delbrück Center have now described in Cell Chemical Biology two new compounds that block this escape route.

The Arl8b protein provides new insights into the mechanisms underlying Alzheimer’s disease. It also has the potential to function as a diagnostic marker. The scientists behind this discovery, a team led by Erich Wanker from the Max Delbrück Center, have published their findings in “Genome Medicine”.

An international research team, including Achim Leutz of the Max Delbrück Center, has discovered that a specific protein controls the conversion of immune cells. If it were possible to intervene in this process, the development of cancer could be prevented.

Some T cells of the immune system are especially sensitive to genetic disturbances within their mitochondrial power plants. Scientists from BIH and Max Delbrück Center have now published their findings in the journal “Nature Genetics”.

Biochemist and physician Leif S. Ludwig of the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has been named a recipient of the 2023 Heinz Maier-Leibnitz Prize, as the German Research Foundation (DFG) announced on June 27th.